TransMedics Group, Inc. (TMDX)
Largest Insider Buys in Sector
TMDX Stock Price History Chart
TMDX Stock Performance
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for …
Insider Activity of TransMedics Group, Inc.
Over the last 12 months, insiders at TransMedics Group, Inc. have bought $0 and sold $68.04M worth of TransMedics Group, Inc. stock.
On average, over the past 5 years, insiders at TransMedics Group, Inc. have bought $2.33M and sold $39.78M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $155,000 was made by Weill David (director) on 2023‑08‑29.
List of Insider Buy and Sell Transactions, TransMedics Group, Inc.
| 2024-12-02 | Sale | Chief Commercial Officer | 1,084 0.0033% | $86.40 | $93,658 | -21.54% | ||
| 2024-11-11 | Sale | Chief Commercial Officer | 1,458 0.0044% | $90.04 | $131,278 | -18.97% | ||
| 2024-11-05 | Sale | director | 6,750 0.0198% | $83.55 | $563,994 | -0.49% | ||
| 2024-11-01 | Sale | Chief Commercial Officer | 1,083 0.0032% | $82.64 | $89,499 | -5.47% | ||
| 2024-10-15 | Sale | President & CEO | 8,625 0.0237% | $132.71 | $1.14M | -38.36% | ||
| 2024-10-01 | Sale | Chief Commercial Officer | 2,958 0.0091% | $148.24 | $438,491 | -41.09% | ||
| 2024-09-16 | Sale | President & CEO | 8,625 0.0262% | $153.42 | $1.32M | -42.52% | ||
| 2024-09-03 | Sale | Chief Commercial Officer | 2,960 0.0089% | $159.60 | $472,404 | -42.23% | ||
| 2024-08-27 | Sale | See Remarks | 10,000 0.03% | $176.02 | $1.76M | -28.71% | ||
| 2024-08-22 | Sale | President & CEO | 25,000 0.0757% | $175.00 | $4.38M | -26.65% | ||
| 2024-08-21 | Sale | President & CEO | 20,000 0.0593% | $171.03 | $3.42M | -25.67% | ||
| 2024-08-15 | Sale | President & CEO | 8,625 0.027% | $169.73 | $1.46M | 0.00% | ||
| 2024-08-08 | Sale | director | 20,000 0.0594% | $159.33 | $3.19M | -17.14% | ||
| 2024-08-07 | Sale | See remarks | 4,289 0.0134% | $152.20 | $652,786 | -8.00% | ||
| 2024-08-06 | Sale | director | 6,750 0.0194% | $149.96 | $1.01M | -14.00% | ||
| 2024-08-01 | Sale | Chief Commercial Officer | 2,958 0.0093% | $156.77 | $463,727 | -10.61% | ||
| 2024-07-15 | Sale | President & CEO | 8,625 0.0263% | $145.17 | $1.25M | 0.00% | ||
| 2024-07-01 | Sale | Chief Commercial Officer | 2,958 0.0094% | $151.40 | $447,853 | 0.00% | ||
| 2024-06-14 | Sale | President & CEO | 8,625 0.0267% | $141.85 | $1.22M | -1.70% | ||
| 2024-06-05 | Sale | See remarks | 703 0.0021% | $135.21 | $95,053 | +3.48% |
Insider Historical Profitability
| Weill David | director | 10732 0.032% | $62.64 | 2 | 4 | +0.77% |
| Basile Edward M | director | 732 0.0022% | $62.64 | 1 | 7 | <0.0001% |
| KANIA EDWIN M JR | director | 302893 0.9025% | $62.64 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $357.79M | 14.69 | 4.84M | +0.21% | +$749,455.86 | 0.02 | |
| BlackRock | $186.6M | 7.66 | 2.52M | -1.04% | -$1.97M | <0.01 | |
| The Vanguard Group | $139.68M | 5.74 | 1.89M | +1.29% | +$1.77M | <0.01 | |
| Macquarie Group | $95.95M | 3.94 | 1.3M | -14.95% | -$16.87M | 0.09 | |
| Driehaus Capital Management LLC | $94.88M | 3.9 | 1.28M | +17.67% | +$14.25M | 0.94 |